SpotQA Ltd is a company that specializes in quality assurance and testing software, with its flagship product being Virtuoso, an application testing and intelligence platform designed for web and mobile browser applications. Founded in 2016 and headquartered in London, SpotQA utilizes advanced technologies such as robotic process automation, natural language processing, and machine learning to enhance its offerings. Virtuoso provides robust QA automation solutions and services, enabling users to improve software quality and accelerate delivery while minimizing defects. The company also offers QA consulting and end-to-end execution services, supported by a team of experts. In addition to its London headquarters, SpotQA has offices in Hyderabad, Pune, and Lisbon, further expanding its reach and capabilities in the digital QA sector.
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.
Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.
Ambit Biosciences is a privately-held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating cancer, inflammatory diseases, and other conditions. The company's lead compound, AC220, is a selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various indications. The clinical pipeline also includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. In addition, Ambit has several preclinical candidates, including CEP-32496, a BRAF inhibitor that has been licensed to Cephalon. Through its innovative research, Ambit aims to improve treatment outcomes for patients suffering from cancer.
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.
Ambit Biosciences is a privately-held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating cancer, inflammatory diseases, and other conditions. The company's lead compound, AC220, is a selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various indications. The clinical pipeline also includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. In addition, Ambit has several preclinical candidates, including CEP-32496, a BRAF inhibitor that has been licensed to Cephalon. Through its innovative research, Ambit aims to improve treatment outcomes for patients suffering from cancer.
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.
Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for pruritus and gastrointestinal diseases. The company's lead product, Asimadoline, is an orally active kappa opioid receptor agonist that targets itching associated with atopic dermatitis and also addresses gastrointestinal conditions such as irritable bowel syndrome and functional dyspepsia. Founded in 2005, Tioga aims to provide effective treatments that offer safety benefits by minimizing typical opioid side effects, thus enhancing patient outcomes in managing these conditions.
Altair Therapeutics is a biopharmaceutical company focused on developing therapeutics to treat human respiratory diseases.
LigoCyte Pharmaceuticals specializes in the development of innovative vaccines and therapeutic monoclonal antibodies aimed at addressing inflammatory and infectious diseases. The company focuses on creating commercial vaccines and biodefense products, including Norovirus VLP Vaccines and an Influenza VLP Vaccine, which offer protection against multiple strains of the virus without causing infection. Additionally, LigoCyte is advancing an anthrax vaccine and the Anti-CD103 Monoclonal Antibody, which plays a role in the retention of activated lymphocytes in areas of inflammation. By concentrating on immunomodulatory drugs that target the underlying disease processes, LigoCyte is well-positioned for growth in the biotechnology sector and is advancing its proprietary products into human clinical testing.
Ambit Biosciences is a privately-held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating cancer, inflammatory diseases, and other conditions. The company's lead compound, AC220, is a selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various indications. The clinical pipeline also includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. In addition, Ambit has several preclinical candidates, including CEP-32496, a BRAF inhibitor that has been licensed to Cephalon. Through its innovative research, Ambit aims to improve treatment outcomes for patients suffering from cancer.
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Asteres Inc. is a company specializing in pharmacy automation technology, founded in 2003 and based in San Diego, California. It develops and installs kiosks and lockers that facilitate the pickup of prescriptions and healthcare products at various locations, including retail stores, hospitals, corporate worksites, and military bases. Asteres is known for its ScriptCenter system, which functions similarly to an ATM, allowing consumers to retrieve and pay for their prescriptions outside of regular pharmacy hours or without waiting in line. This innovation not only extends pharmacy service hours without requiring additional staff but also enhances customer convenience, encouraging shoppers to remain in-store. Asteres further supports its products with integration of IT, pharmacy management, and payment systems, along with marketing and maintenance services. The company's expertise in healthcare automation stems from a management team with significant experience in retail pharmacy and healthcare systems.
Concurrent Thinking Limited specializes in the design and implementation of large-scale computing infrastructures and software tailored for high-performance computing. Based in Warwick, United Kingdom, the company offers a range of data center infrastructure management solutions, including concurrentCOMMAND, which integrates with facilities management systems to optimize energy efficiency, and concurrentCONTROL, a platform for monitoring power, environmental conditions, servers, and operating systems within data centers. Additionally, Concurrent Thinking provides support and maintenance services to its clients, which include IT, environmental, and financial sectors, as well as facilities management. Established in 2009 and formerly known as Retromaze Limited, the company rebranded in June 2010 to reflect its focus on innovative approaches to system management and scalable computing solutions.
Sequel Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes novel and clinical-stage drug candidates for patients with cardiovascular disease. The company was founded in 2007 and is based in San Diego, California.
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
TargeGen, Inc. is a biopharmaceutical company specializing in vascular biology, focused on discovering and developing small molecule kinase inhibitors. These inhibitors target critical processes such as vascular leakage, vascular proliferation, and inflammation. TargeGen's product offerings address a range of serious medical conditions, including heart attack, cancer, eye diseases, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome (ARDS), brain inflammation, and various central nervous system disorders. The company plays a significant role in treating conditions like macular degeneration, diabetic macular edema, and diabetic retinopathy. Founded in 2002 and based in San Diego, California, TargeGen was acquired by Sanofi Aventis in 2010.
NovaCardia
Series B in 2007
NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.
Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.
Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.
Proprius Pharmaceuticals is a San Diego-based drug developer focused on rheumatology and autoimmune diseases. The company offers two early clinical-stage therapeutic candidates comprising a product to treat pain and a product to treat rheumatoid arthritis. Proprius Pharmaceuticals was founded in 2005.
Morphotek is a prominent life science company focused on developing innovative biological products for the treatment of cancer, inflammatory conditions, and infectious diseases. Established in 2000, Morphotek specializes in the discovery and development of monoclonal antibodies (mABs) and conducts research and clinical development programs for its own drug candidates. The company targets various ailments, including ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The foundation of Morphotek's technology lies in morphogenics, co-invented by Dr. Nicholas Nicolaides during his post-graduate studies at Johns Hopkins Medical School, alongside co-founders Dr. Philip Sass and Dr. Luigi Grasso. This proprietary technology has significantly advanced Morphotek's capabilities in creating novel pharmaceutical products and therapeutic targets.
NovaCardia
Series B in 2006
NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.
Cabrellis Pharmaceuticals
Series A in 2006
Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.
Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for pruritus and gastrointestinal diseases. The company's lead product, Asimadoline, is an orally active kappa opioid receptor agonist that targets itching associated with atopic dermatitis and also addresses gastrointestinal conditions such as irritable bowel syndrome and functional dyspepsia. Founded in 2005, Tioga aims to provide effective treatments that offer safety benefits by minimizing typical opioid side effects, thus enhancing patient outcomes in managing these conditions.
Hypnion is a neuroscience drug discovery and development company that develops novel therapeutics for the treatment of central nervous system disorders. The company develops treatments for sleep- and wake-alertness disorders and circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform that is able to measure drugs’ impact on sleep and wake parameters. Hypnion is acquired by Eli Lilly and Company. Hypnion was founded in 2000 and is based in Worcester, Massachusetts.
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
TargeGen, Inc. is a biopharmaceutical company specializing in vascular biology, focused on discovering and developing small molecule kinase inhibitors. These inhibitors target critical processes such as vascular leakage, vascular proliferation, and inflammation. TargeGen's product offerings address a range of serious medical conditions, including heart attack, cancer, eye diseases, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome (ARDS), brain inflammation, and various central nervous system disorders. The company plays a significant role in treating conditions like macular degeneration, diabetic macular edema, and diabetic retinopathy. Founded in 2002 and based in San Diego, California, TargeGen was acquired by Sanofi Aventis in 2010.
Adiana, Inc. engages in the development and testing of transcervical sterilization system for permanent birth control. It develops Complete TCS, which consists of a radiofrequency generator, delivery catheter, and implantable matrix. The company was founded in 1997 and is based in Redwood City, California. As of March 16, 2007, Adiana, Inc. is a subsidiary of CYTYC Corp.
Ambit Biosciences is a privately-held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating cancer, inflammatory diseases, and other conditions. The company's lead compound, AC220, is a selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various indications. The clinical pipeline also includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. In addition, Ambit has several preclinical candidates, including CEP-32496, a BRAF inhibitor that has been licensed to Cephalon. Through its innovative research, Ambit aims to improve treatment outcomes for patients suffering from cancer.
NovaCardia
Series A in 2005
NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.
Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.
Predix is a drug discovery and development company that uses a novel 3D Discovery and Optimization Engine for GPCR drug candidates and is taking its novel compounds into the clinic. The discovery engine uses a sophisticated proprietary algorithm, PREDICT(TM), for computer modeling the 3D structure of any GPCR target; advanced technologies HYPERION(TM) and RISS(TM) for rapid high-throughput in silico screening of millions of compounds against the 3D in silico model of the target; and an integrated medicinal/computational platform for lead optimization based on the receptor's structure (ICELR-3D(TM)) and predictive algorithms for important drug properties. In August, Predix and Physiome Sciences Inc. combined companies and expanded the expertise into ion channel drug discovery.
Cellective Therapeutics was founded with technology created by Dr. Tom Tedder, a recognized world leader in B-cell biology and Chairman of the Department of Immunology at Duke University. Dr. Tedder's team focused on research done in B cells, cells that form an important component of the normal immune system and are hyperactive in people with autoimmune disorders. This hyperactivity of B cells can cause tissue inflammation and organ system dysfunction. With autoimmune diseases like lupus, multiple sclerosis and rheumatoid arthritis, the body actually rejects itself, as if organs were transplanted from someone else. Cellective's research focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.
Cellective Therapeutics
Series A in 2004
Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.
Imagine Pharma is a drug discovery and development company specializing in innovative regenerative therapies for diabetes and cardiovascular diseases. The company focuses on creating therapeutic drugs for conditions such as type I and type II diabetes, pulmonary hypertension, and managing cholesterol and blood pressure. By employing an agile and efficient approach to drug discovery, Imagine Pharma aims to significantly enhance the efficacy and safety of existing treatments. Their platform supports preclinical candidates, facilitating early treatment options through polypeptide and oral delivery methods specifically designed for cardiovascular disorders.
Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.
Morphotek is a prominent life science company focused on developing innovative biological products for the treatment of cancer, inflammatory conditions, and infectious diseases. Established in 2000, Morphotek specializes in the discovery and development of monoclonal antibodies (mABs) and conducts research and clinical development programs for its own drug candidates. The company targets various ailments, including ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The foundation of Morphotek's technology lies in morphogenics, co-invented by Dr. Nicholas Nicolaides during his post-graduate studies at Johns Hopkins Medical School, alongside co-founders Dr. Philip Sass and Dr. Luigi Grasso. This proprietary technology has significantly advanced Morphotek's capabilities in creating novel pharmaceutical products and therapeutic targets.
TargeGen, Inc. is a biopharmaceutical company specializing in vascular biology, focused on discovering and developing small molecule kinase inhibitors. These inhibitors target critical processes such as vascular leakage, vascular proliferation, and inflammation. TargeGen's product offerings address a range of serious medical conditions, including heart attack, cancer, eye diseases, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome (ARDS), brain inflammation, and various central nervous system disorders. The company plays a significant role in treating conditions like macular degeneration, diabetic macular edema, and diabetic retinopathy. Founded in 2002 and based in San Diego, California, TargeGen was acquired by Sanofi Aventis in 2010.
Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.
Conforma Therapeutics
Series C in 2003
Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California
NovaCardia
Venture Round in 2003
NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.
Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.
Hypnion is a neuroscience drug discovery and development company that develops novel therapeutics for the treatment of central nervous system disorders. The company develops treatments for sleep- and wake-alertness disorders and circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform that is able to measure drugs’ impact on sleep and wake parameters. Hypnion is acquired by Eli Lilly and Company. Hypnion was founded in 2000 and is based in Worcester, Massachusetts.
Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.
TargeGen, Inc. is a biopharmaceutical company specializing in vascular biology, focused on discovering and developing small molecule kinase inhibitors. These inhibitors target critical processes such as vascular leakage, vascular proliferation, and inflammation. TargeGen's product offerings address a range of serious medical conditions, including heart attack, cancer, eye diseases, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome (ARDS), brain inflammation, and various central nervous system disorders. The company plays a significant role in treating conditions like macular degeneration, diabetic macular edema, and diabetic retinopathy. Founded in 2002 and based in San Diego, California, TargeGen was acquired by Sanofi Aventis in 2010.
Dynavax Technologies Corporation is a biopharmaceutical company headquartered in Emeryville, California, specializing in the discovery and development of novel vaccines and treatments for infectious diseases. The company markets HEPLISAV-B, an adjuvanted vaccine for the prevention of hepatitis B infection in adults. Dynavax utilizes its unique Toll-like Receptor Immune Modulation Platform to stimulate the body's immune responses, which is integral to its product development. In addition to its commercial offerings, Dynavax has an active immuno-oncology portfolio, featuring candidates such as SD-101 and DV281. The company is engaged in various research collaborations aimed at developing COVID-19 vaccines, partnering with organizations like Clover Biopharmaceuticals, the University of Queensland, and CEPI. These partnerships reflect Dynavax's commitment to addressing urgent health challenges through innovative vaccine solutions. Founded in 1996, Dynavax has evolved from its original name, Double Helix Corporation, to focus on enhancing immune responses for better disease prevention and treatment.
Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.
Gryphon Therapeutics is a biopharmaceutical company focused on the development of performance-enhanced protein therapeutics. Its products combine chemically synthesized protein backbones with polyethylene glycols such as molecules to create potent medications.
Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.
AGY Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for central nervous system (CNS) diseases. The company targets neurodegenerative diseases, CNS injuries, stroke, cognitive disorders, and schizophrenia, with a diverse pipeline that includes both clinical and preclinical programs. AGY has developed a proprietary platform for functional gene discovery, which aids in identifying and validating therapeutic targets that can modulate disease progression. Key programs in their pipeline include treatments for stroke, cognitive impairment, and schizophrenia, as well as various antibody and receptor therapies. Founded in 1998 and based in South San Francisco, California, AGY Therapeutics aims to address significant unmet medical needs in the CNS therapeutic landscape.
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.
Ambit Biosciences is a privately-held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating cancer, inflammatory diseases, and other conditions. The company's lead compound, AC220, is a selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various indications. The clinical pipeline also includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. In addition, Ambit has several preclinical candidates, including CEP-32496, a BRAF inhibitor that has been licensed to Cephalon. Through its innovative research, Ambit aims to improve treatment outcomes for patients suffering from cancer.
Variagenics
Funding Round in 2000
Variagenics develops and commercializes proprietary gene variance detection technology to streamline drug development.
Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.